0.7606
price down icon3.73%   -0.0295
after-market 시간 외 거래: .71 -0.0506 -6.65%
loading
전일 마감가:
$0.7901
열려 있는:
$0.76
하루 거래량:
213.11K
Relative Volume:
0.88
시가총액:
$48.18M
수익:
$9.53M
순이익/손실:
$-44.61M
주가수익비율:
-0.8358
EPS:
-0.91
순현금흐름:
$-38.32M
1주 성능:
-23.94%
1개월 성능:
-36.62%
6개월 성능:
-7.15%
1년 성능:
-57.03%
1일 변동 폭
Value
$0.705
$0.80
1주일 범위
Value
$0.705
$1.05
52주 변동 폭
Value
$0.45
$2.26

Cue Biopharma Inc Stock (CUE) Company Profile

Name
명칭
Cue Biopharma Inc
Name
전화
617-949-2680
Name
주소
40 GUEST STREET, BOSTON, MA
Name
직원
0
Name
트위터
@cuebiopharma
Name
다음 수익 날짜
2025-03-31
Name
최신 SEC 제출 서류
Name
CUE's Discussions on Twitter

CUE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CUE
Cue Biopharma Inc
0.7606 48.18M 9.53M -44.61M -38.32M -0.91
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-03-13 개시 Jefferies Buy
2023-06-26 재개 Oppenheimer Outperform
2022-11-21 개시 Piper Sandler Overweight
2022-01-13 개시 H.C. Wainwright Buy
2022-01-03 개시 Craig Hallum Buy
2020-11-24 개시 Berenberg Buy
2020-04-09 개시 Stifel Buy
2020-01-28 개시 BTIG Research Buy
2020-01-22 개시 JMP Securities Mkt Outperform
모두보기

Cue Biopharma Inc 주식(CUE)의 최신 뉴스

pulisher
Apr 02, 2025

Cue Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Cue Biopharma’s Strategic Focus and Financial Outlook - TipRanks

Apr 02, 2025
pulisher
Apr 01, 2025

What's Going On With Cue Biopharma Shares Tuesday? - Benzinga

Apr 01, 2025
pulisher
Mar 31, 2025

Cue Biopharma earnings missed by $0.04, revenue fell short of estimates - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Yahoo Finance

Mar 31, 2025
pulisher
Mar 24, 2025

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times

Mar 24, 2025
pulisher
Mar 22, 2025

Bleichroeder LP Increases Stake in Cue Biopharma Inc - GuruFocus.com

Mar 22, 2025
pulisher
Mar 21, 2025

[Top 3] Best Biotech Penny Stocks to Buy in 2025Finbold - Finbold - Finance in Bold

Mar 21, 2025
pulisher
Mar 19, 2025

Cue Biopharma (CUE) Projected to Post Quarterly Earnings on Wednesday - Defense World

Mar 19, 2025
pulisher
Mar 17, 2025

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - Nasdaq

Mar 17, 2025
pulisher
Mar 13, 2025

Cue Biopharma appoints Pasha Sarraf to board By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 12, 2025

Cue Biopharma Appoints Pasha Sarraf to Board - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Cue Biopharma appoints Pasha Sarraf to board - Investing.com

Mar 12, 2025
pulisher
Mar 01, 2025

Cue Biopharma (NASDAQ:CUE) Trading Down 3.8%What's Next? - MarketBeat

Mar 01, 2025
pulisher
Feb 24, 2025

Larger animals really are more prone to cancer, debunking ‘Peto’s paradox’ - Study Finds

Feb 24, 2025
pulisher
Feb 21, 2025

Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace

Feb 21, 2025
pulisher
Feb 20, 2025

HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Feb 20, 2025
pulisher
Feb 17, 2025

Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE) - ACCESS Newswire

Feb 17, 2025
pulisher
Feb 12, 2025

Pancreatic Adenocarcinoma Market Growth Projections - openPR

Feb 12, 2025
pulisher
Feb 05, 2025

Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat

Feb 05, 2025
pulisher
Jan 31, 2025

Artiva Biotherapeutics expands board with industry veteran - MSN

Jan 31, 2025
pulisher
Jan 30, 2025

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - The Manila Times

Jan 30, 2025
pulisher
Jan 29, 2025

Artiva Biotherapeutics appoints new director and committee members - MSN

Jan 29, 2025
pulisher
Jan 29, 2025

Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com Nigeria

Jan 29, 2025
pulisher
Jan 29, 2025

Artiva expands Board with appointment of Dan Baker, M.D - TipRanks

Jan 29, 2025
pulisher
Jan 29, 2025

Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan

Jan 29, 2025
pulisher
Jan 13, 2025

Geode Capital Management LLC Increases Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

Geode Capital Management LLC Purchases 212,394 Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) - Defense World

Jan 13, 2025
pulisher
Jan 06, 2025

HPV16+ Cancer Clinical and Non-Clinical Studies, Key - openPR

Jan 06, 2025
pulisher
Jan 02, 2025

Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 8.0% in December - MarketBeat

Jan 02, 2025
pulisher
Jan 02, 2025

Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World

Jan 02, 2025
pulisher
Dec 27, 2024

The definitive Boston biotech layoff tracker for 2024 - The Business Journals

Dec 27, 2024
pulisher
Dec 25, 2024

Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com

Dec 25, 2024
pulisher
Dec 19, 2024

Cue Biopharma CEO Daniel Passeri buys $30,900 in stock By Investing.com - Investing.com Australia

Dec 19, 2024
pulisher
Dec 18, 2024

Cue Biopharma CEO Daniel Passeri buys $30,900 in stock - Investing.com India

Dec 18, 2024
pulisher
Dec 18, 2024

Insider Buying: Daniel Passeri Acquires 30,000 Shares of Cue Bio - GuruFocus.com

Dec 18, 2024
pulisher
Dec 18, 2024

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock - MarketBeat

Dec 18, 2024
pulisher
Dec 16, 2024

Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5% - MarketBeat

Dec 16, 2024
pulisher
Dec 13, 2024

Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus sparks debate - Investing.com Australia

Dec 13, 2024
pulisher
Nov 29, 2024

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 29, 2024
pulisher
Nov 29, 2024

Cue Biopharma Grants 200,000 Share Option Award to New Development Chief - StockTitan

Nov 29, 2024
pulisher
Nov 29, 2024

Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail

Nov 29, 2024
pulisher
Nov 29, 2024

Strong week for Cue Biopharma (NASDAQ:CUE) shareholders doesn't alleviate pain of five-year loss - Simply Wall St

Nov 29, 2024

Cue Biopharma Inc (CUE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
자본화:     |  볼륨(24시간):